PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CR UK research backs liquid biopsy for breast cancer

Cancer Research UK scientists are working on a new blood test able to identify rare mutations in advanced breast cancer, which could give patients quicker access to the most effective treatments.

As part of the plasmaMATCH clinical trial, funded by Stand Up To Cancer, a joint fundraising campaign from Cancer Research UK and Channel 4, the researchers detected mutations in tumour DNA, which had been shed into the bloodstream.

They found specific weaknesses in the breast cancer DNA that could be targeted with medicine, “suggesting that this blood test could be a better way of guiding treatment than standard tissue biopsies, which can be painful and take longer to analyse”.

“The choice of targeted treatment we give to patients is usually based on the mutations found in the original breast tumour. But their cancer can have different mutations after it has moved to other parts of the body,” explained Professor Nicholas Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden.

“We have now confirmed that blood tests can quickly give us a bigger picture of the mutations are present within multiple tumours throughout the body, getting the results back to patients accurately and faster than we could before.

“This is a huge step in terms of making decisions in the clinic, particularly for those women with advanced breast cancer who could quickly be put on new targeted treatments matched to their cancer if it evolves to become drug resistant.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026